Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
24.8
USD
|
-0.48%
|
|
+1.97%
|
-19.97%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,134
|
3,391
|
3,224
|
2,707
|
4,433
|
3,684
|
-
|
-
|
Enterprise Value (EV)
1 |
2,003
|
3,231
|
3,089
|
2,863
|
4,993
|
4,238
|
4,339
|
4,492
|
P/E ratio
|
-7.93
x
|
-11.1
x
|
-7.02
x
|
-5.11
x
|
-5.8
x
|
-5.38
x
|
-6.34
x
|
-10.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.6
x
|
20.6
x
|
17.1
x
|
11
x
|
14.5
x
|
10.3
x
|
7.32
x
|
4.38
x
|
EV / Revenue
|
14.7
x
|
19.6
x
|
16.4
x
|
11.7
x
|
16.4
x
|
11.9
x
|
8.62
x
|
5.34
x
|
EV / EBITDA
|
-8.9
x
|
-12.9
x
|
-8.58
x
|
-6.4
x
|
-7.14
x
|
-6.21
x
|
-6.28
x
|
-13.5
x
|
EV / FCF
|
-6.84
x
|
-14.3
x
|
-8.34
x
|
-6.98
x
|
-9.09
x
|
-6.47
x
|
-7
x
|
-14.4
x
|
FCF Yield
|
-14.6%
|
-6.98%
|
-12%
|
-14.3%
|
-11%
|
-15.4%
|
-14.3%
|
-6.94%
|
Price to Book
|
8.18
x
|
12.4
x
|
6.82
x
|
30.8
x
|
-13.1
x
|
-18.9
x
|
-16.3
x
|
-15
x
|
Nbr of stocks (in thousands)
|
89,344
|
101,868
|
118,372
|
135,477
|
143,062
|
148,555
|
-
|
-
|
Reference price
2 |
23.88
|
33.29
|
27.24
|
19.98
|
30.99
|
24.80
|
24.80
|
24.80
|
Announcement Date
|
2/25/20
|
2/25/21
|
2/17/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
136.5
|
164.4
|
188.5
|
245.4
|
305.2
|
356.7
|
503.1
|
842
|
EBITDA
1 |
-225.1
|
-251.1
|
-359.8
|
-447
|
-699
|
-682.4
|
-691.1
|
-332.2
|
EBIT
1 |
-235.2
|
-265.2
|
-375.1
|
-457.3
|
-709.6
|
-673.3
|
-617.6
|
-366.1
|
Operating Margin
|
-172.38%
|
-161.32%
|
-199.03%
|
-186.39%
|
-232.51%
|
-188.74%
|
-122.77%
|
-43.49%
|
Earnings before Tax (EBT)
1 |
-253.6
|
-292.7
|
-436.4
|
-480.2
|
-747
|
-722.8
|
-687.8
|
-446.2
|
Net income
1 |
-254.3
|
-294.1
|
-434.7
|
-481.5
|
-749.6
|
-722.9
|
-672
|
-427.7
|
Net margin
|
-186.37%
|
-178.87%
|
-230.63%
|
-196.26%
|
-245.59%
|
-202.66%
|
-133.58%
|
-50.8%
|
EPS
2 |
-3.010
|
-3.010
|
-3.880
|
-3.910
|
-5.340
|
-4.614
|
-3.910
|
-2.421
|
Free Cash Flow
1 |
-292.9
|
-225.6
|
-370.6
|
-410.3
|
-549.5
|
-654.6
|
-619.8
|
-311.6
|
FCF margin
|
-214.64%
|
-137.21%
|
-196.64%
|
-167.23%
|
-180.05%
|
-183.51%
|
-123.2%
|
-37.01%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/25/21
|
2/17/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
46.76
|
56.12
|
53.11
|
65.22
|
67.73
|
59.3
|
65.21
|
77.23
|
79.07
|
83.69
|
78.95
|
88.68
|
92.19
|
95.57
|
-
|
EBITDA
1 |
-100.1
|
-95.43
|
-87.28
|
-86.1
|
-125.6
|
-148
|
-145.6
|
-233
|
-144.9
|
-175.5
|
-174
|
-189
|
-171
|
-180
|
-
|
EBIT
1 |
-103.6
|
-99.08
|
-89.83
|
-88.32
|
-127.7
|
-151.5
|
-148.2
|
-235.5
|
-147.7
|
-178.3
|
-172.2
|
-168.8
|
-163.5
|
-168.5
|
-
|
Operating Margin
|
-221.61%
|
-176.53%
|
-169.15%
|
-135.41%
|
-188.54%
|
-255.44%
|
-227.19%
|
-304.97%
|
-186.75%
|
-213.01%
|
-218.13%
|
-190.34%
|
-177.32%
|
-176.3%
|
-
|
Earnings before Tax (EBT)
1 |
-115.3
|
-113
|
-94.24
|
-95.14
|
-130.8
|
-160
|
-159.3
|
-244.3
|
-158.4
|
-185.1
|
-182.2
|
-180.2
|
-175.2
|
-179.8
|
-
|
Net income
1 |
-112.7
|
-113
|
-94.62
|
-95.64
|
-131.1
|
-160.1
|
-159.8
|
-244.8
|
-158.9
|
-186.1
|
-179.8
|
-176.6
|
-169.5
|
-184.7
|
-
|
Net margin
|
-241.06%
|
-201.3%
|
-178.17%
|
-146.65%
|
-193.63%
|
-270.02%
|
-244.98%
|
-316.99%
|
-201%
|
-222.31%
|
-227.71%
|
-199.12%
|
-183.86%
|
-193.27%
|
-
|
EPS
2 |
-0.9600
|
-0.9500
|
-0.8000
|
-0.8000
|
-1.090
|
-1.210
|
-1.170
|
-1.780
|
-1.110
|
-1.280
|
-1.237
|
-1.136
|
-1.082
|
-1.151
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/28/21
|
2/17/22
|
5/5/22
|
8/4/22
|
10/27/22
|
2/23/23
|
5/4/23
|
8/3/23
|
10/26/23
|
2/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
156
|
560
|
553
|
654
|
808
|
Net Cash position
1 |
130
|
161
|
135
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.3486
x
|
-0.8004
x
|
-0.811
x
|
-0.947
x
|
-2.433
x
|
Free Cash Flow
1 |
-293
|
-226
|
-371
|
-410
|
-550
|
-655
|
-620
|
-312
|
ROE (net income / shareholders' equity)
|
-108%
|
-109%
|
-127%
|
-193%
|
-
|
-
|
-609%
|
-44.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-42.6%
|
-33.2%
|
-50.2%
|
-59.8%
|
-69.6%
|
-
|
Assets
1 |
-
|
-
|
1,020
|
1,450
|
1,493
|
1,208
|
965.2
|
-
|
Book Value Per Share
2 |
2.920
|
2.680
|
3.990
|
0.6500
|
-2.360
|
-1.310
|
-1.520
|
-1.660
|
Cash Flow per Share
2 |
-
|
-2.250
|
-3.240
|
-3.250
|
-3.820
|
-3.610
|
-2.870
|
-
|
Capex
1 |
42.3
|
6.24
|
7.29
|
9.88
|
13.3
|
12.6
|
13.3
|
14
|
Capex / Sales
|
30.97%
|
3.8%
|
3.87%
|
4.03%
|
4.35%
|
3.54%
|
2.65%
|
1.66%
|
Announcement Date
|
2/25/20
|
2/25/21
|
2/17/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
24.8
USD Average target price
44.12
USD Spread / Average Target +77.92% Consensus |
1st Jan change
|
Capi.
|
---|
| -19.97% | 3.68B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|